08:00 , Nov 13, 2000 |  BC Week In Review  |  Company News

Biostar, York Medical Inc. deal

York acquired exclusive global rights to Biostar's Norelin immunopharmaceutical that stimulates the immune system to produce antibodies to gonadotropin-releasing hormone (GnRH) to treat hormone-dependent cancers such as ovarian, breast, uterine, or prostate cancers. York said...
07:00 , Oct 2, 2000 |  BC Week In Review  |  Company News

Biostar, Pfizer deal

BioStar and PFE's Agouron Pharmaceuticals Inc. (La Jolla, Calif.) division amended their 1998 agreement to grant Agouron a non-exclusive license to BioStar's technology for optically detecting nucleic acids within a specific field of use. BioStar's...
07:00 , Aug 28, 2000 |  BC Week In Review  |  Company News

Biostar, MetaMorphix deal

MetaMorphix acquired animal health assets from Biostar, including Biostar's immunopharmaceutical technology for producing specific antibodies against a target. MetaMorphix said the technology could potentially generate more meat per animal, improve feed conversion, produce leaner meat...
07:00 , Aug 14, 2000 |  BC Week In Review  |  Clinical News

Nucleic acid hybridization detection technology regulatory update

TMO's BioStar Inc. subsidiary (Boulder, Colo.) received U.S. Patent No. 6,060,237 covering the use of thin molecular films to optically detect nucleic acid hybridization. Thermo Electron Corp. (TMO), Waltham, Mass.   Product: Nucleic acid hybridization...
08:00 , Jan 17, 2000 |  BioCentury  |  Regulation

Enough flu to go around

The FDA last week felt it necessary to issue a Public Health Advisory reminding physicians to pay attention to their prescribing practices in patients with influenza, as it appears that physicians may have been overly...
08:00 , Nov 15, 1999 |  BC Week In Review  |  Clinical News

Test kit for Clostridium difficile toxin A regulatory update

The FDA granted marketing clearance for TBA's CdTOX A OIA kit to detect C. difficile bacteria toxin A. The kit is produced by TBA's BioStar Inc. subsidiary (Boulder, Colo.). Thermo BioAnalysis Corp. (TBA), Santa Fe,...
07:00 , Jul 26, 1999 |  BC Week In Review  |  Company News

Genomica Corp. management update

Genomica Corp., Boulder, Colo.   Business: Enabling technology   Hired: Teresa Ayers as CEO and a director, formerly president and CEO of BioStar Inc.  ...
07:00 , Jun 21, 1999 |  BC Week In Review  |  Company News

Thermo BioAnalysis management update

Thermo BioAnalysis Corp. (TBA), Boulder, Colo.   Business: Supply/Service   Promoted: Noel Doheny to president and CEO of TBA's BioStar Inc. subsidiary from EVP of commercial development at BioStar; he replaces Teresa Ayers, who resigned...
08:00 , Feb 22, 1999 |  BC Week In Review  |  Clinical News

Norelin: Began Phase I/II trial

Biostar Inc., Saskatoon, Saskatchewan   Product: Norelin   Business: Cancer   Therapeutic category: Immune stimulation   Target: Gonadotropin-releasing hormone (GnRH)   Description: Therapeutic vaccine against GnRH to control sex hormone levels   Indication: Treat prostate...
08:00 , Dec 7, 1998 |  BC Week In Review  |  Clinical News

Biota, Thermo BioAnalysis regulatory update

TBA's BioStar Inc. subsidiary (Boulder, Colo.) received 510 (k) marketing clearance for its Flu OIA test for influenza A and B. The test was developed with BTAHY. Biota Holdings Ltd. (ASX:BTA; BTAHY), Melbourne, Australia  ...